Danielle Bodicoat

Dr. Danielle Bodicoat

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2016 in Journal of Medical Internet Research
Verified
Journal Article
Open access
Michelle HadjiconstantinouMichelle Hadjiconstantinou
Michelle Hadjiconstantinou
JBJo Byrne
Jo Byrne
DBDanielle Bodicoat
Danielle Bodicoat
NRNoelle Robertson
Noelle Robertson
HEHelen Eborall
Helen Eborall
MDMelanie J Davies
Melanie J Davies
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

1 February 2019 in Public Health Research
Verified
Journal Article
Closed access
DHDeirdre M. Harrington
Deirdre M. Harrington
MDMelanie J Davies
Melanie J Davies
DBDanielle Bodicoat
Danielle Bodicoat
JCJoanna M Charles
Joanna M Charles
YCYogini V Chudasama
Yogini V Chudasama
CECharlotte Edwardson
Charlotte Edwardson
Background: Physical activity (PA) levels among adolescent girls in the UK are low. ‘Girls Active’, developed by the Youth Sport Trust (YST), has been designed to increase girls’ PA levels.Objective: To understand the effectiveness and cost-effectiveness of the Girls Active programme.Design: A two-arm cluster randomised controlled trial.Setting: State secondary schools in the Midlands, UK.Participants: Girls aged between 11 and 14 years.Intervention: Girls Active involves teachers reviewing PA, sport and physical education provision, culture and practices in their school; attending training; creating action plans; and effectively working with girls as peer leaders to influence decision-making and to promote PA to their peers. Support from a hub school and the YST is offered.Main outcome measures: The change in objectively measured moderate to vigorous intensity PA (MVPA) levels at 14 months. Secondary outcomes included changes in overall PA level (mean acceleration), light PA levels, sedentary time, body composition and psychosocial outcomes. Cost-effectiveness and process evaluation (qualitative and quantitative) data were collected.Results: Twenty schools and 1752 pupils were recruited; 1211 participants provided complete primary outcome data at 14 months. No difference was found in mean MVPA level between groups at 14 months [1.7 minutes/day, 95% confidence interval (CI) –0.8 to 4.3 minutes/day], but there was a small difference in mean MVPA level at 7 months (2.4 minutes/day, 95% CI 0.1 to 4.7 minutes/day). Significant differences between groups were found at 7 months, but not at 14 months, in some of the objective secondary outcomes: overall PA level represented by average acceleration (1.39 mg, 95% CI 0.1 to 2.2 mg), after-school sedentary time (–4.7 minutes/day, 95% CI –8.9 to –0.6 minutes/day), overall light PA level (5.7 minutes/day, 95% CI 1.0 to 10.5 minutes/day) and light PA level on school days (4.5 minutes/day, 95% CI 0.25 to 8.75 minutes/day). Minor, yet statistically significant, differences in psychosocial measures at 7 months were found in favour of control schools. Significant differences in self-esteem and identified motivation in favour of intervention schools were found at 7 and 14 months, respectively. Subgroup analyses showed a significant effect of the intervention for those schools with higher numbers of pupils at 14 months. Girls Active was well received by teachers, and they reported that implemented strategies and activities were having a positive impact in schools. Barriers to implementation progress included lack of time, competing priorities and the programme flexibility. Implementation costs ranged from £2054 (£23/pupil) to £8545 (£95/pupil) per school. No differences were found between groups for health-related quality-of-life scores or frequencies, or for costs associated with general practitioner, school nurse and school counsellor use.Conclusions: Girls Active may not have had an effect on the random 90 girls per school included in the evaluation. Although we included a diverse sample of schools, the results may not be generalisable to all schools. Girls Active was viewed positively but teachers did not implement as many aspects of the programme as they wanted. The intervention was unlikely to have a wide impact and did not have an impact on MVPA level at 14 months. Capitalising on the opportunities of a flexible programme like this, while also learning from the stated barriers to and challenges of long-term implementation that teachers face, is a priority for research and practice.Trial registration: Current Controlled Trials ISRCTN10688342.Funding: This project was funded by the National Institute for Health Research (NIHR) Public Health Research programme and will be published in full inPublic Health Research; Vol. 7, No. 5. See the NIHR Journals Library website for further project information. The YST funded the intervention. This study was undertaken in collaboration with the Leicester Clinical Trials Unit, a UK Clinical Research Collaboration-registered clinical trials unit in receipt of NIHR Clinical Trials Unit support funding. Neither the YST nor the NIHR Clinical Trials Unit had any involvement in the Trial Steering Committee, data analysis, data interpretation, data collection or writing of the report. The University of Leicester authors are supported by the NIHR Leicester–Loughborough Biomedical Research Unit (2012–17), the NIHR Leicester Biomedical Research Centre (2017–22) and the Collaboration for Leadership in Applied Health Research and Care East Midlands. These funders had no involvement in the Trial Steering Committee, the data analysis, data interpretation, data collection or writing of the report.

20 April 2024 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
CSCécile van Steen
Cécile van Steen
LCLorenzo Celico
Lorenzo Celico
ESErik Spaepen
Erik Spaepen
THTim Hagenacker
Tim Hagenacker
Sven G. MeuthSven G. Meuth
Sven G. Meuth
SISergio Iannazzo
Sergio Iannazzo
Introduction Efgartigimod and ravulizumab, both approved for treating acetylcholine receptor auto-antibody-positive (AChR-Ab+) generalized myasthenia gravis (gMG), have not been directly compared. This paper assessed comparative effects of efgartigimod vs. ravulizumab for treating adults with AChR-Ab+ gMG using indirect treatment comparison methods. Methods The matching-adjusted indirect comparison used data from two randomized trials of adult men and women. The ADAPT (efgartigimod vs. placebo; individual patient data available) population was reweighted to match the CHAMPION (ravulizumab vs. placebo; index study; aggregate data available) population. The relative effect of efgartigimod versus placebo was estimated in this reweighted population and compared with the observed ravulizumab versus placebo effect to estimate the efgartigimod versus ravulizumab effect. The outcomes were Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and Myasthenia Gravis Quality of Life 15-item-revised scale (MG-QoL15r) assessed as cumulative effect (area under the curve; AUC) over 26 weeks (primary) and change from baseline at 4 weeks and time of best response (week 4 for efgartigimod; week 26 for ravulizumab). Results For MG-QoL15r, efgartigimod had a statistically significant improvement compared with ravulizumab over 26 weeks [mean difference (95% confidence interval): – 52.6 (– 103.0, – 2.3)], at week 4 [– 4.0 (– 6.6, – 1.4)], and at time of best response [– 3.9 (– 6.5, – 1.3)]. Efgartigimod had a statistically significant improvement over ravulizumab in MG-ADL at week 4 [– 1.9 (– 3.3, – 0.5)] and at time of best response [– 1.4 (– 2.8, 0.0)] and in QMG at week 4 [– 3.2 (– 5.2, – 1.2)] and at time of best response [– 3.0 (– 5.0, – 1.0)]. For AUC over 26 weeks, improvements were not significantly different between efgartigimod and ravulizumab for MG-ADL [– 8.7 (– 36.1, 18.8)] and QMG [– 13.7 (– 50.3, 22.9)]. Conclusion Efgartigimod may provide a faster and greater improvement over 26 weeks in quality of life than ravulizumab in adults with AChR-Ab+ gMG. Efgartigimod showed faster improvements in MG-ADL and QMG than ravulizumab.

11 October 2014 in Diabetic Medicine
Verified
Journal Article
Open access
PDF file
HDH. M. Dallosso
H. M. Dallosso
DBDanielle Bodicoat
Danielle Bodicoat
MCMichael J Joseph Campbell
Michael J Joseph Campbell
MCM. E. Carey
M. E. Carey
MDMelanie J Davies
Melanie J Davies
SHS. Heller
S. Heller
Aims: To compare the effectiveness and acceptability of self‐monitoring of blood glucose with self‐monitoring of urine glucose in adults with newly diagnosed Type 2 diabetes.Methods: We conducted a multi‐site cluster randomized controlled trial with practice‐level randomization. Participants attended a structured group education programme, which included a module on self‐monitoring using blood glucose or urine glucose monitoring. HbA1c and other biomedical measures as well as psychosocial data were collected at 6, 12 and 18 months. A total of 292 participants with Type 2 diabetes were recruited from 75 practices.Results: HbA1c levels were significantly lower at 18 months than at baseline in both the blood monitoring group [mean (se) −12 (2) mmol/mol; −1.1 (0.2) %] and the urine monitoring group [mean (se) −13 (2) mmol/mol; −1.2 (0.2)%], with no difference between groups [mean difference adjusted for cluster effect and baseline value = −1 mmol/mol (95% CI −3, 2); −0.1% (95% CI −0.3, 0.2)]. Similar improvements were observed for the other biomedical outcomes, with no differences between groups. Both groups showed improvements in total treatment satisfaction, generic well‐being, and diabetes‐specific well‐being, and had a less threatening view of diabetes, with no differences between groups at 18 months. Approximately one in five participants in the urine monitoring arm switched to blood monitoring, while those in the blood monitoring arm rarely switched (18 vs 1% at 18 months; P < 0.001).Conclusions: Participants with newly diagnosed Type 2 diabetes who attended structured education showed similar improvements in HbA1c levels at 18 months, regardless of whether they were assigned to blood or urine self‐monitoring.

22 May 2020 in Pilot and Feasibility Studies
Verified
Journal Article
Open access
PDF file
MDMelanie J Davies
Melanie J Davies
CKCaroline A. Kristunas
Caroline A. Kristunas
LHLisa Huddlestone
Lisa Huddlestone
AAAbualbishr Alshreef
Abualbishr Alshreef
DBDanielle Bodicoat
Danielle Bodicoat
LGLaura J. Gray
Laura J. Gray
Background: Structured self-management education (SSME) for people with type 2 diabetes mellitus (T2DM) improves biomedical and psychological outcomes, whilst being cost-effective. Yet uptake in the UK remains low. An ‘Embedding Package’ addressing barriers and enablers to uptake at patient, health care professional and organisational levels has been developed. The aim of this study was to test the feasibility of conducting a subsequent randomised controlled trial (RCT) to evaluate the Embedding Package in primary care, using a mixed methods approach. Methods: A concurrent mixed methods approach was adopted. Six general practices in the UK were recruited and received the intervention (the Embedding Package). Pseudonymised demographic, biomedical and SSME data were extracted from primary care medical records for patients recorded as having a diagnosis of T2DM. Descriptive statistics assessed quantitative data completeness and accuracy. Quantitative data were supplemented and validated by a patient questionnaire, for which two recruitment methods were trialled. Where consent was given, the questionnaire and primary care data were linked and compared. The cost of the intervention was estimated. An integrated qualitative study comprising ethnography and stakeholder and patient interviews explored the process of implementation, sustainability of change and ‘fit’ of the intervention. Qualitative data were analysed using a thematic framework guided by the Normalisation Process Theory (NPT). Results: Primary care data were extracted for 2877 patients. The primary outcome for the RCT, HbA1c, was over 90% complete. Questionnaires were received from 423 (14.7%) participants, with postal invitations yielding more participants than general practitioner (GP) prompts. Ninety-one percent of questionnaire participants consented to data linkage. The mean cost per patient for the Embedding Package was £8.94, over a median follow-up of 162.5 days. Removing the development cost, this reduces to £5.47 per patient. Adoption of ethnographic and interview methods in the collection of data was appropriate, and the use of NPT, whilst challenging, enhanced the understanding of the implementation process. The need to delay the collection of patient interview data to enable the intervention to inform patient care was highlighted. Conclusions: It is feasible to collect data with reasonable completeness and accuracy for the subsequent RCT, although refinement to improve the quality of the data collected will be undertaken. Based on resource use data collected, it was feasible to produce cost estimates for each individual component of the Embedding Package. The methods chosen to generate, collect and analyse qualitative data were satisfactory, keeping participant burden low and providing insight into potential refinements of the Embedding Package and customisation of the methods for the RCT. Trial registration: ISRCTN, ISRCTN21321635, Registered 07/07/2017—retrospectively registered.

11 February 2020 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
DBDanielle Bodicoat
Danielle Bodicoat
MSMinouk J. Schoemaker
Minouk J. Schoemaker
MJMichael E. Jones
Michael E. Jones
EMEmily McFadden
Emily McFadden
JGJames Griffin
James Griffin
ASAnthony J. Swerdlow
Anthony J. Swerdlow
As a consequence of responding to colleagues who asked about the publication of the original article [1], the authors have determined that the data published in Table 4 of the paper are incorrect.